Management ChangeAug 3, 2026, 07:41 AM
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
AI Summary
Helus Pharma announced the appointment of Michael Halstead as its new Chief Executive Officer, effective immediately. Mr. Halstead brings 25 years of industry experience, including his recent role as President of Intra-Cellular Therapies, Inc., where he was instrumental in the successful development and commercialization of CAPLYTA® and led the company's US$14.6 billion sale to Johnson & Johnson. His appointment comes as Helus Pharma advances HLP003 through late-stage clinical development, with topline data from its pivotal Phase 3 study expected in Q4 2026, and continues development of HLP004.
Key Highlights
- Michael Halstead appointed Chief Executive Officer of Helus Pharma, effective immediately.
- Mr. Halstead previously served as President of Intra-Cellular Therapies, Inc.
- He led Intra-Cellular Therapies' US$14.6 billion sale to Johnson & Johnson in 2025.
- Helus Pharma expects topline data from APPROACH Phase 3 study for HLP003 in Q4 2026.
- HLP003 is being developed as an adjunctive treatment for Major Depressive Disorder (MDD).
- HLP004 is a short-acting compound in Phase 2 development for Generalized Anxiety Disorder.
- The company holds over 350 patent applications and more than 100 granted patents worldwide.
Price Impact
More from HELP